god gave burdensalso shoulders
New Robotic Surgery Technique Maintains Sexual
Function After Prostate Cancer Surgery
The SMART Technique (Samadi Modified Advanced Robotic Technique) Enhances
Surgical Precision and Maintains Sexual Wellbeing After Prostate Cancer
Dr. David Samadi, Vice Chairman, Department of Urology, and Chief of Robotics
and Minimally Invasive Surgery at The Mount Sinai Medical Center knows the wide
range of emotions and fears that men with prostate
cancer face. As a robotic
prostatectomy and prostate
cancer treatment expert, Dr. Samadi cares for the total patient, helping
them deal with all aspects of treatment, recovery and cure. Robotic
prostatectomy procedures, performed to remove the prostate gland and surrounding
cancer, can provide excellent cancer cure results, though many men fear the
potential side effects of the surgery. Top on their list of concerns: will they
be able to have and enjoy sex
after prostate cancer treatment?
Dr. Samadi understands this concern. “For most men, sexual function is
equally as important as eliminating prostate cancer. Many of their fears about
sex after surgery are carry-overs from what they know of older open and
laparoscopic prostatectomy techniques. Thanks to robotic
surgery, these fears can be greatly reduced.” Historically, the prostate
gland was removed through invasive surgery during which surgeons had a difficult
time sparing the tiny nerve bundles responsible for erectile and sexual
function. Often, a man’s ability to have sex after surgery was negatively
impacted. With the advent of robotic surgery techniques, experienced surgeons
like Dr. Samadi have an enhanced view of the prostate gland, allowing increased
precision and dexterity. As a result, the risk of damage to the nerves vital to
sexual function is significantly diminished.
When treating his prostate cancer patients, Dr. Samadi employs a
start-to-finish approach, including an individualized evaluation of sexual
function prior to surgery and on-going, post-surgical assessments of options to
aid the return of sexual function. “I consider robotic surgery successful when
the cancer is cured and the patient has full continence and potency. All three
criteria must be met for me to consider the surgery a success.” Dr. Samadi dubs
this whole-patient approach, “Treatment Trifecta.”
Dr. Samadi customizes robotic surgery with his own SMART
(Samadi Modified Advanced Robotic Technique) method. Using the da Vinci
System, the commonly recommended treatment for localized prostate cancer, Dr.
Samadi is able to perform highly precise movements at the surgical site:
cancerous tissue is cleanly removed and critical nerves are spared. By not
opening the surrounding fascia around the prostate and not suturing the dorsal
vein complex, Dr. Samadi has improved the quality of men’s post operative sex
life. Ultimately, this leads to faster recovery and an improved outlook for
regaining sexual function and urinary continence.
“Men want to know they can return to a normal life when this is all over.
They want the cancer gone and they want to move on and enjoy sex the way they
always have,” says Dr. Samadi. While the resumption of sexual potency can take
up to 12 months or more, Dr. Samadi assures patients that this is within the
normal course of recovery. His comprehensive approach to prostate cancer
treatment and sexual wellbeing continues beyond surgery. “It’s not uncommon for
men to experience some ED immediately following prostatectomy procedures, but
this is not an indication of their long-term sexual potency. I continue to work
with patients to achieve the complete results they desire.”
More can be seen from prostate cancer expert, Dr. Samadi, who is also part of
the Fox News Team.
Cancer Treatment Options Compared: Robotic Surgery vs. Watchful Waiting
Surgery on Good Day New York
(The Mount Sinai Hospital / Mount Sinai School of Medicine) In the first long-term study of the health impacts of the World Trade Center (WTC) collapse on Sept. 11, 2001, researchers at The Mount Sinai Medical Center in New York have found substantial and persistent mental and physical health problems among Sept. 11 first responders and recovery workers. www.eurekalert.org
Join the Ovarian Cancer National Alliance and hundreds of women with ovarian cancer for a unique benefit concert. The alternative rock band N.E.D. (which stands for No Evidence of Disease) is made up of gynecologic oncologists from around the country. By day, they fight gynecologic cancer; by night, they raise awareness of women’s cancers through their original rock music.
Hyatt Regency on Capitol Hill 400 New Jersey Ave. NWWashington, DC 20001
Sunday, July 10, 2011 7:00 PM
Approximately 21,000 women will be diagnosed with ovarian cancer this year, and about 15,000 will die from the disease. This concert benefits the Ovarian Cancer National Alliance, a nonprofit organization that advances the interests of women with ovarian cancer. More information about the Alliance is available at http://www.ovariancancer.org
The musicians in N.E.D. are all board-certified gynecologic oncologists who have dedicated their careers to fighting women’s cancers. Additional details about the band members are available at http://www.nedtheband.com/band.html
John Boggess, MD, guitar, vocals. Dr. Boggess is Associate Professor of Obstetrics & Gynecology and Fellowship Program Director, Division of Gynecologic Oncology at the University of North Carolina School of Medicine.
Joanie Hope, MD, guitar, vocals. Dr. Hope is a Gynecologic Oncology Fellow at the New York University School of Medicine.
Nimesh Nagarsheth, MD, drums, percussion. Dr. Nagarsheth is on faculty at Mount Sinai Medical Center in New York City and Englewood Hospital and Medical Center in Englewood, New Jersey.
William “Rusty” Robinson, MD, bass, harmonica. Dr. Robinson is the Director of Clinical Research at the Harrington Cancer Center in Amarillo, Texas.
John Soper, MD, guitar. John hails from Iowa but now calls North Carolina home. He is the Hendricks Professor of Obstetrics and Gynecology at the University of North Carolina School of Medicine.
Will Winter, MD, guitar. Will is an gynecologic oncologist at Northwest Cancer Specialists in Vancouver, Washington and Portland, Oregon.
PHILADELPHIA (Reuters Health) May 03 - Researchers are a step closer to knowing which hepatitis C patients are more likely to lose their grafts after liver transplantation.
According to study results announced yesterday at the American Transplant Congress in Philadelphia, hepatitis C patients with the IL28B CC or CT genotype have better graft survival and longer times to histological recurrence than recipients with the TT genotype.
Hepatitis C viremia inevitably recurs after liver transplantation, leading to high rates of cirrhosis and graft loss. The new findings could mean that directing lower-risk organs (e.g., from younger donors, or with shorter cold ischemia times) to higher-risk recipients might improve their outcomes.
"This is clearly something that could have clinical implications," senior investigator Dr. Barbara Murphy from Mount Sinai Medical Center in New York City told Reuters Health. "There's already a lab-based assay available, so we could genotype the recipients. Certain labs have this up and going."
But Dr. Murphy won't say transplant programs should act now on these results. Her study, while large, was retrospective. "If you're going to change organ allocation -- if you're going to give one group preference for better organs -- you'd better have data" from randomized trials, she said.
Studies in hepatitis C patients who still have their native liver had already pointed to an impact from the IL28B gene, Dr. Murphy said. Individuals with the favorable polymorphism are more likely to have spontaneous clearance or a sustained virologic response to interferon-based therapy. In a plenary session talk yesterday, her colleague Dr. Sridhar R. Allam reported on a study of 620 adult liver recipients for whom DNA samples were available for genotyping of IL28B (rs12979860); the cohort included 327 hepatitis C virus HCV-positive patients.
The research team also had genotype data for a subgroup of 377 consecutive donor DNA samples, and IL28B gene expression data from RNA isolated from pre-implantation liver biopsies of 33 donors. Dr. Allam reported significantly better five-year graft survival with the IL28B CC or CT genotype vs. the TT genotype (61.8% vs. 47.9%, p=0.02) in patients with HCV infection. In the non-HCV control group, however, there was no difference in graft survival based on IL28B genotype. Also, he said, recipients with C allele had delayed mean time to histological HCV recurrence after LT (25 vs. 15 months, p=0.02).
There was no association of donor IL28B genotype with graft survival, and no effect of IL28B genotype on IL28 RNA expression.
IL28 is known to affect innate immunity, but it's not clear why it impacts graft survival, Dr. Allam said. When researchers do design randomized trials, among the most important things they'll want to see is whether any interventions -- such as shifting better-quality livers to patients at higher risk for graft loss -- will actually change outcomes, Dr. Murphy said.
Also, it will likely be important to consider IL28B genotype in trials of new protease inhibitors for HCV. "You would think the polymorphism would point to outcome," Dr. Murphy said. "They'll need to look for this in trial populations, to make sure it's not skewing the data."
Robotic prostatectomy expert, Dr. David B. Samadi, Vice Chairman, Department of Urology, and Chief of Robotics and Minimally Invasive Surgery at The Mount Sinai Medical Center, announced the launch feeds.bignewsnetwork.com
You can link to this article on your web site using following code:
We're looking for comments that are interesting, substantial or highly amusing. If your comments are excessively self-promotional (use your real name, no keywords please), obnoxious, or even worse, boring, you will be banned from commenting. Your comment must be related to the post. Please do not comment on how great or wonderful the post is. All comments are moderated and, if approved, will display in less than 24 hours.